Zhongsheng Pharmaceutical's Subsidiary Signs Licensing Agreement for RAY1225 Injection with Qilu Pharmaceutical

Gelonghui January 16thZhongsheng Pharmaceutical(002317.SZ) announced,Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd. ("Raynovent"), a holding subsidiary of Zhongsheng Pharmaceutical, and Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical") signed a "License Agreement" on January 16, 2026. Raynovent granted Qilu Pharmaceutical the rights to manufacture and commercially sell RAY1225 Injection (the "Licensed Product") in the China region (including mainland China, Hong Kong, Macao, and Taiwan, collectively referred to as the "Licensed Territory"). Raynovent retains all rights, ownership, and interests in the licensed intellectual property. After the Licensed Product receives marketing approval from the drug regulatory authorities, Raynovent will be the Marketing Authorization Holder (MAH). Meanwhile, Raynovent continues to hold all rights, ownership, and interests of RAY1225 Injection outside of China, including but not limited to clinical development, manufacturing, new drug registration, sales, and marketing promotion.

Under the terms of the licensing agreement, Raynovent will receive an upfront payment and milestone payments totaling RMB 10 billion, including an upfront payment of RMB 2 billion, development and sales milestone payments up to a combined total of RMB 8 billion, and subsequent double-digit royalties on net sales of the licensed product after its market launch.

The licensed product RAY1225 Injection, developed by raynovent, is an innovative peptide drug with global independent intellectual property rights. It exhibits dual agonist activity on GLP-1 and GIP receptors and, due to its excellent pharmacokinetic properties, has the potential to be an ultra-long-acting drug administered once every two weeks. Currently, the Phase III clinical trial (REBUILDING-2 study) evaluating the safety and efficacy of RAY1225 Injection for treating obese/overweight patients in China, the Phase III clinical trial (SHINING-3) assessing the safety and efficacy of RAY1225 Injection in combination with oral hypoglycemic drugs for type 2 diabetes patients compared with Semaglutide Injection, and the placebo-controlled Phase III clinical trial (SHINING-2) examining the safety and efficacy of RAY1225 Injection as monotherapy for type 2 diabetes patients have all successfully completed participant enrollment. raynovent will continue to uphold a rigorous approach, advancing the Phase III clinical trials of RAY1225 Injection in a high-quality, efficient, and scientifically standardized manner.